ArticlemSphere2023
Nationwide molecular epidemiology of carbapenemase-producing
Article in mSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Risk and prognosis of infection and colonisation by carbapenemase-producingInfection prevention in practice · 2026Article
- Epidemiological and Molecular Surveillance of Multiresistant Citrobacter freundii Complex in a Tertiary Care Hospital: A Retrospective Cohort Study.The Journal of infectious diseases · 2026Article
- Characterization of a conjugative IncFII/IncR plasmid harboring blaBMC microbiology · 2026Article
- Resolving plasmid-encoded carbapenem resistance dynamics and reservoirs in a hospital setting through nanopore sequencing.Microbial genomics · 2026Article
- Emergence of a novel NDM-4-producingIDCases · 2026Article
- Distribution of ST116 carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Identification of plasmid encodedIranian journal of microbiology · 2025Article
- NDM- or VIM-producing Citrobacter spp. in Poland, 2011-19: high genetic diversity with broader representation of ST8, ST18 and ST22 global clones.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Optimal treatment of Imipenem and meropenem against bloodstream infections caused by the Citrobacter spp.BMC infectious diseases · 2025Article
- Identification of CMY-190, a novel chromosomally encoded AmpC β-lactamase, and plasmid-encoded KPC-2 in a clinical isolate ofFrontiers in microbiology · 2025Article
- Urban wastewater overflows as hotspots for dissemination of bacteria producing extended-spectrum β-lactamases and carbapenemases in the Suquía River, Argentina.Frontiers in microbiology · 2025Article
- Persistence of OXA-48-producing ST-22Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Molecular, Genetic, and Biochemical Characterization of OXA-484 Carbapenemase, a Difficult-to-Detect R214G Variant of OXA-181.Microorganisms · 2024Article
- Plasmid genomic epidemiology of carbapenem-hydrolysing class D β-lactamase (CDHL)-producingMicrobial genomics · 2024Article
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaAnnals of clinical microbiology and antimicrobials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceThe emergence of carbapenemase producers in Enterobacterales mostly involves
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.